Presentation on theme: "Hyperglycemia in inpatients: a call for intensive care Individualizing therapy for optimal results."— Presentation transcript:
Hyperglycemia in inpatients: a call for intensive care Individualizing therapy for optimal results
Hyperglycemia-scope of the problem 5.7 million hosp annually, At least 1/4 have diabetes, unknown more have hospital related hyperglycemia Diabetes now 8% of the population. 20 million! Hyperglycemia common in acute illness (50% of ACS patients). Patients not known to be diabetic are hyperglycemic in hospital undiagnosed, insulin-resistant population, hyperglycemia secondary to illness Cost of inpatient diabetes care-$40 Bln DM pts $13,243 vs. $ 2,560 non-diabetics per admission “The most expensive chronic illness in the US” Source: American Association of Endocrinologists
An evolving recognition of importance of glucose control. Historically not an issue, no evidence for improved outcomes, even 1995 study no short term benefit. Hyperglycemia expected, even good? “Stress hyperglycemia” Higher CABG wound infection rates with hyperglycemia Increased mortality and LOS in CABG patients with hyperglycemia CVA; 2001: SICU; 2006: MICU AACE recommendations of hyperglycemia ADA guidelines AACE + ADA
The dangers of hyperglycemia Patients with AMI, elevated glucose correlates with increased mortality and infarct size. Correlates with CHF 1 CVA patients: elevated glucose assoc with increased mortality 2 Increasing blood glucose concentrations are associated with adverse clinical outcomes in patients with AECOPD 3 Hyperglycemia on admission is independently associated with adverse outcomes in patients with CAP 4 Increased risk of wound infection post-CABG 5 1. Inpatient diabetes and glycemic control: A call to action. AACE, Parsons MW, et al. Acute hyperglycemia adversely affects stroke outcome: a magnetic resonance imaging and spectroscopy study. Ann Neurol 2002;52: E H Baker, et al. Hyperglycaemia is associated with poor outcomes in patients admitted to hospital with acute exacerbations of chronic obstructive pulmonary disease Thorax, April 1, 2006; 61(4): F. A. McAlister, et al. The Relation Between Hyperglycemia and Outcomes in 2,471 Patients Admitted to the Hospital With Community-Acquired Pneumonia. Diabetes Care, April 1, 2005; 28(4): SH Golden, et al. Perioperative glycemic control and the risk of infectious complications in a cohort of adults with diabetes. Diabetes Care 22:
Normoglycemia proven benefits 2001 study NEJM, SICU patients with strict BS control Reduced mortality by 34% Sepsis 46% Renal failure 41% Transfusion 41% Polyneuropathy 44% Van Den Berghe G, Wouters P, Weekers F, et al. Intensive insulin therapy in critically ill patients. N Engl J Med. 2001;345:
Normoglycemia proven benefits! Recent study in MICU For patients who stayed >3 days, reduced mortality 18%, less renal dysfunction, prolonged mechanical ventilation. Patients < 3 days, increased mortality?? 1 Recent meta-analysis showed 15% decrease in mortality in a variety of settings Van den Berghe G, Wilmer A, Hermans G, et al. Intensive insulin therapy in the medical ICU N Engl J Med. 2006; 354: Pittas AG, Siegel RD, Lau J. Insulin therapy for critically ill hospitalized patients:a meta-analysis of randomized, control trials. Arch Inter Med. 2004; 164:
Normoglycemia proven benefits DIGAMI- intensive insulin therapy 29% reduction in mortality at 1 year. (Independent effect of insulin?) CABG patients: Intensive therapy reduces sternal infections by 57%, 66% reduction in mortality 1 MICU patients: intensive therapy: catheter sepsis decrease 33.5%, LOS 0.25 days 2 1. Furnary AP, Zerr KJ, Grunkemeier GL, Starr A. Continuous intravenous insulin infusion reduces the incidence of deep sternal wound infection in diabetic patients after cardiac surgical procedures. Ann Thorac Surg 1999;67:
Normoglycemia : How to do it? Goal: physiologic mimicry Options Oral meds ? Problems…Discontinue? Oral+Insulins? Change to insulin for better control? SQ or IV? Sliding scale? Meal time insulins? Drip? Pumps?
Sliding scale insulin History and what’s wrong Abandoned! Retroactive not proactive Chasing our tail, esp. Type I Basal insulin Mealtimes/ eating Variation in disease state Dangers of hypoglycemia
It’s as easy as BBC FS Glucose qAC and qHS Check HbA1C Then: BASAL: NPH/Glargine 0.2units/kg/day or drip BOLUS: Aspart/ Lispro 0.05units/kg meals CORRECTION: Both long acting and short acting
General recommendations for SQ insulin therapy Treatment goal for patient on SQ regimen is pre-prandial glucose level of mg/dL, Insulin therapy should provide both basal and prandial insulin support when needed Basal insulin: --Long-acting (glargine, detemir) - provides peakless insulin coverage for ~24 hours --Intermediate-acting (NPH): - Peak effect ~ 4-6 hours after administration with about 12 hour duration of activity Prandial and correction insulin: --Short-acting (Regular) - Peak effect ~ 2-3 hours after administration with about 6 hour duration of activity. --Rapid-acting (lispro, aspart, glulisine) - Peak effect ~ 1 hour after administration with about 2 hour duration of activity.
Initiating SQ insulin therapy Already on Insulin * *All patients with type 1 diabetes and most patients with insulin-dependent type 2 diabetes require basal insulin, even when NPO. 1. Estimate starting daily insulin doses: For patients with insulin dependent diabetes If good oral intake is expected, continue usual home insulin regimen If poor oral intake is expected or if NPO: o basal insulin: glargine, detemir at ~ 75% of home dose OR o intermediate-acting insulin: NPH at ~ 50% of home dose o short-acting insulin: hold rapid-acting (lispro, aspart, glulisine) and replace with Regular insulin sliding scale.
Considerations Lower doseHigher dose No previous DMElevated HbA1C Glucose sl elevatedGlucose high Poor POgood to excessive PO Impaired renal functionMetabolic stress Corticosteroids
Initiating insulin: New to Insulin For most patients with type 2 diabetes (or being initiated to insulin therapy), total daily insulin dose can be estimated at 0.3 to 0.6 units/kg/day The dosing range represents varying degrees of insulin resistance: dose kg
2. Estimate scheduled doses. Glargine insulin - about 50% of total daily dose Lispro insulin - about 50% of total daily dose divided into the 3 meals Example: For an 80 kg patient who is new to insulin - - glargine insulin 12 units SQ at hs - lispro insulin 4 units SQ before each meal (hold if NPO or intake poor) NPH insulin - about 44% of total daily dose before breakfast meal, and about 17% of total daily dose at hs Regular insulin - about 22% of total daily dose before breakfast meal, and about 17% of total daily dose before supper meal Example: For an 80 kg patient who is new to insulin - - NPH insulin 11 units SQ before breakfast and 4 units SQ at hs - Regular insulin 5 units SQ before breakfast and 4 units SQ before supper meal Initiating SQ insulin therapy
3. Add correction insulin doses as desired Monitoring of glucose levels and titration of insulin doses at least daily a. If blood glucose levels are consistently too high/low, the total daily insulin dose can be adjusted by shifting to a column to the right/left on the total daily dose table above b. Insulin doses are adjusted based on subsequent glucose levels: i. glargine and evening NPH insulin doses based on glucose levels at 0200 and before breakfast ii. mealtime insulin doses based on glucose levels before the next meal and at hs c. RN may administer as little as 50% of SCHEDULED insulin dose if: i. Patient has had change to NPO status and blood glucose is < 150 mg/dL. ii. Patient has had decline in PO intake to less than 33% from previous and blood glucose is < 150 mg/dL. Initiating SQ insulin therapy
Insulin drip Indication for intravenous insulin infusion among nonpregnant adults with established diabetes or hyperglycemia Diabetic ketoacidosis and nonketotic hyperosmolar state A General preoperative, intraoperative, and postoperative care C Postoperative period following heart surgery B Organ transplantation E MI or cardiogenic shock A Stroke E Exacerbated hyperglycemia during high-dose steroid therapy E NPO status in type 1 diabetes E Critically ill surgical patient requiring mechanical ventilation A Dose-finding strategy, anticipatory to initiation or reinitiating of subcutaneous insulin therapy in type 1 or type 2 diabetes C
Insulin drip Advantages Tightest control Good absorption Rapid adjustments Easy standardized Disadvantages Frequent monitoring (ICU/IMCU needed?) Nursing time! Catheter complications Problems when switching to SQ regimen Rapid Glucose shifts?
What about hypoglycemia ? BG level ≤40 mg/dL was 5.2% in intensive insulin-treated patients versus 0.8% in conventionally treated patients. 1 But… In a national survey, Cohen et al. found that 11% of serious medication errors resulted from insulin misadministration. 2 Need for frequent monitoring Need for separate protocol, oral and IV D50 administration. Prevents “overshooting” 1. van den Berghe G, Wouters PJ, Bouillon R, Weekers F, Verwaest C, Schetz M, et al. Outcome benefit of intensive insulin therapy in the critically ill: insulin dose versus glycemic control. Crit Care Med 2003;31: Cohen MR, Proulx SM, Crawford SY. Survey of hospital system and common serious medication errors. J Healthc Risk Manag 1998;18:16-27.
Logistics Multidisciplinary steering committee Standardized order sets Glycemic management team. Monitoring results. Hypoglycemic protocol Nutrition Diabetes education
Cost vs. benefits Each increased 50 mg/dL of blood glucose added 0.76 LOS in diabetic CABG patients. 1 Use of diabetes team 56% reduction LOS $2353/patient. 2 Intensive therapy in SICU saves $40K/year. Furnary AP, et al. Postoperative hyperglycemia prolongs length of stay in hospitalized patients with diabetic CABG patients. Circulation. 2000; 102 (18) II-556. Koproski J et al. Effects of an intervention by a diabetes team in hospitalized patients with diabetes. Diabetes Care. 1997; 20:
Barriers Fear of hypoglycemia Nursing time, data collection. Lack of standardization Changing insulin requirements Skepticism to benefits of good control. Multiple transfers of patients.
Further research Refinement of protocols Impact of hyperglycemia in development of DM Non critically ill patients: goals? Continuous monitoring (pulse ox of the future) Role of feedings